These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37931975)

  • 1. Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study.
    Bergamini A; Ramaswami R; Froeling F; Papanastasopoulos P; Short D; Aguiar X; Savage PM; Sarwar N; Kaur B; Saso S; Fotopoulou C; Sharma A; Rustin GJS; Seckl M
    Int J Gynecol Cancer; 2023 Nov; 33(11):1750-1756. PubMed ID: 37931975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study.
    Tamauchi S; Kajiyama H; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Utsumi F; Niimi K; Suzuki S; Kikkawa F
    Am J Obstet Gynecol; 2018 Oct; 219(4):385.e1-385.e7. PubMed ID: 30086295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
    Tangir J; Zelterman D; Ma W; Schwartz PE
    Obstet Gynecol; 2003 Feb; 101(2):251-7. PubMed ID: 12576247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.
    Chu R; Liu P; Chen J; Cheng X; Li K; Che Y; Wang J; Li L; Zhang X; Yao S; Song L; Zhao Y; Huang C; Xue Y; Pan X; Li J; Chen Z; Jiang J; Kong B; Song K
    J Gynecol Oncol; 2023 Mar; 34(2):e12. PubMed ID: 36890292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility after chemotherapy for ovarian germ cell tumours.
    Pektasides D; Rustin GJ; Newlands ES; Begent RH; Bagshawe KD
    Br J Obstet Gynaecol; 1987 May; 94(5):477-9. PubMed ID: 2437953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report.
    Ghalleb M; Bouzaiene H; Slim S; Hadiji A; Hechiche M; Ben Hassouna J; Rahal K
    J Med Case Rep; 2017 Dec; 11(1):350. PubMed ID: 29248013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
    de La Motte Rouge T; Pautier P; Duvillard P; Rey A; Morice P; Haie-Meder C; Kerbrat P; Culine S; Troalen F; Lhommé C
    Ann Oncol; 2008 Aug; 19(8):1435-1441. PubMed ID: 18408223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Vasta FM; Cormio G; Cassani C; Bergamini A; Scarfone G; Ferrandina G; De Vivo R; Marinaccio M; Danese S; Raspagliesi F; Pignata S; Mangili G
    Gynecol Oncol; 2024 Feb; 181():28-32. PubMed ID: 38104526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
    Newlands ES
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
    Solheim O; Tropé CG; Rokkones E; Kærn J; Paulsen T; Salvesen HB; Hagen B; Vereide AB; Fosså SD
    Gynecol Oncol; 2015 Feb; 136(2):224-9. PubMed ID: 25511159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jun; 137(3):418-22. PubMed ID: 25842162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.
    Gaffan J; Holden L; Newlands ES; Short D; Fuller S; Begent RH; Rustin GJ; Seckl MJ
    Br J Cancer; 2003 Nov; 89(10):1849-54. PubMed ID: 14612891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
    Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
    J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies.
    Mann JR; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendszus KR
    Cancer; 1989 May; 63(9):1657-67. PubMed ID: 2467734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
    Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
    Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy.
    Yoo SC; Kim WY; Yoon JH; Chang SJ; Chang KH; Ryu HS
    Acta Obstet Gynecol Scand; 2010; 89(1):126-30. PubMed ID: 19878051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.